Funded in part by Abiogen Pharma SpA
Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion
Giannini S, Mazzaferro S, Minisola S, De Nicola L, Rossini M, Cozzolino M
Endocrine · 12 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Expert or government fact sheet (classified by our AI screen)
- Main outcome
- No health outcome
Who paid for it
- Funding
- Industry funded
- Company
- Abiogen Pharma SpA
- Authors
- At least one author declares a financial tie to industry
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2017-07-19 · Endocrine · vol. 59 · issue 2 · pp. 242–259
- Publisher
- Springer Science+Business Media
- Cited
- 18 citations · more than 87% of similar papers · 2.1× the field average
- References
- 202 works
- Access
- Open access (hybrid journal) · CC-BY
- Research areas
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Pharmacological Effects and Toxicity Studies
- Keywords
- Medicine, Cholecalciferol, Vitamin D and neurology, Kidney disease, Kidney transplantation, vitamin D deficiency, Kidney, Vitamin, Internal medicine, Population, Disease, Endocrinology, Intensive care medicine, Environmental health
- MeSH
- humans, vitamin d deficiency, cholecalciferol, renal insufficiency, chronic
6 authors
From IT
- Sandro GianniniUniversity of Padua
- Sandro MazzaferroSapienza University of Rome
- Salvatore MinisolaSapienza University of Rome
- Luca De NicolaUniversity of Campania "Luigi Vanvitelli"; University of Naples Federico II
- Maurizio RossiniUniversity of Verona
- Mario Gennaro Cozzolino · correspondingUniversity of Milan; Ospedale San Paolo
Abstract
Vitamin D is recognized to play an essential role in health and disease. In kidney disease, vitamin D analogs have gained recognition for their involvement and potential therapeutic importance. Nephrologists are aware of the use of oral native vitamin D supplementation, however, uncertainty still exists with regard to the use of this treatment option in chronic kidney disease as well as clinical settings related to chronic kidney disease, where vitamin D supplementation may be an appropriate therapeutic choice. Two consecutive meetings were held in Florence in July and November 2016 comprising six experts in kidney disease (N = 3) and bone mineral metabolism (N = 3) to discuss a range of unresolved issues related to the use of cholecalciferol in chronic kidney disease. The panel focused on the following six key areas where issues relating to the use of oral vitamin D remain controversial: (1) vitamin D and parathyroid hormone levels in the general population, (2) cholecalciferol in chronic kidney disease, (3) vitamin D in cardiovascular disease, (4) vitamin D and renal bone disease, (5) vitamin D in rheumatological diseases affecting the kidney, (6) vitamin D and kidney transplantation.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.